Phendimetrazine Tartrate (Phendimetrazine Tartrate) Patent Expiration, LOE Window & CMS Spending

Phendimetrazine Tartrate (Phendimetrazine Tartrate) by Acertis: Off-Patent Genericized (AB Competition), 3 AB generics, $7K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAcertis
FDA Application & PathwayN018074 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$7K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$7K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 26.4% 2-yr change)